Toronto, Ontario–(Newsfile Corp. – June 24, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat Addiction, announced today that globally renowned neuroscientist and addiction researcher, Prof. David Nutt, has joined its executive team as Chief Research Officer. This appointment is driven by…


Previous articleExclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange
Next articleWesana Health Partners with University of South Carolina